Rangering i aksjer
#20256
Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research,... Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of new therapeutics. Its core mission revolves around pioneering innovative solutions for hepatotoxicity-free acetaminophen and addressing various fatty liver conditions. The company's robust pipeline features SNP-610, a drug candidate currently advancing through Phase II clinical trials in Taiwan for the treatment of non-alcoholic steatohepatitis (NASH). Another early-stage compound, SNP-630, is also in preclinical development, targeting NASH. Beyond liver disease, Sinew Pharma is progressing SNP-810 for its analgesic and antipyretic properties. Furthermore, the firm is developing SNP-830 and SNP-840, positioned as liver-safe pain medications specifically for the United States market. Established in 2014, Sinew Pharma Inc. maintains its headquarters in Taipei City, Taiwan.
Handel Sinew Pharma Inc. (6634)
Pris 6634 pris med markedsverdi på B
Markedsverdi av Sinew Pharma Inc.(6634)
Markedsverdi: $135.79M
Per August 2026 har Sinew Pharma Inc. en markedsverdi på $135.79M. Dette gjør Sinew Pharma Inc. til det 20256th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Sinew Pharma Inc. fra 2017 til 2026
6634 sammenlignet med topp 5 mest populære stocks
| Pris på 6634 |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.142T
|
+3,786,689.09%
|
|
|
|
|
$4.540T
|
+3,343,429.45%
|
|
|
|
|
$4.157T
|
+3,061,214.35%
|
|
|
|
|
$3.635T
|
+2,676,880.30%
|
|
|
|
|
$2.798T
|
+2,060,400.83%
|
